01.06.2008 | Original Article
Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters
Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 3/2008
Einloggen, um Zugang zu erhalten